Rho associated kinase (ROCK) inhibitors and their use in treating disease
The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory polypeptide blocks ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, a novel locus identifying a new class of inhibitory drugs. The peptides described will be useful against a number of important diseases such as heart disease, pulmonary hypertension, arterial hypertension, glaucoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, or acute myeloid leukemia.
1. A method of treating cardiovascular disease and/or conditions involving remodeling comprising administering to a subject in need thereof a pharmaceutical composition comprising (a) a peptide consisting of 4-30 residues and exhibiting the sequence ERTYSPS (SEQ ID NO: 69) and (b) a pharmaceutically acceptable buffer, excipient or diluent.
2. The method of claim 1 , wherein the peptide consists of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 30 residues.
3. The method of claim 1 , wherein the peptide consists of the sequence ERTYSPS (SEQ ID NO: 69).
4. The method of claim 1 , wherein the peptide comprises the sequence ERTYSPSTAVRS (SEQ ID NO: 49).
5. The method of claim 1 , wherein the peptide consisting of the sequence ERTYSPSTAVRS (SEQ ID NO: 49).
6. The method of claim 1 , wherein the peptide further comprises one or more D-amino acid residues.
7. The method of claim 1 , wherein the peptide further comprises all D-amino acid residues.
8. The method of claim 1 , wherein administering the inhibitor is performed intramuscularly, intravenously or by direct injection into cardiac tissue.
9. The method of claim 1 , wherein administering the inhibitor comprises oral, transdermal, sustained release, controlled release, delayed release, suppository, or sublingual administration.
10. The method of claim 1 , further comprising administering said peptide to said subject at least a second time.
11. The method of claim 10 , wherein said peptide is administered chronically to said subject.
12. The method of claim 1 , further comprising administering to said patient a second heart disease therapy.
13. The method of claim 12 , wherein said second therapy is selected from the group consisting of a second ROCK inhibitor, a beta blocker, an ionotrope, a diuretic, ACE-I, All antagonist, BNP, or a Ca ++ channel blocker.
14. The method of claim 1 , wherein treating comprises improving one or more symptoms of heart failure.
15. The method of claim 14 , wherein said one or more improved symptoms comprises increased exercise capacity, increased cardiac ejection volume, increased cardiac ejection fraction, decreased left ventricular end diastolic pressure, decreased pulmonary capillary wedge pressure, increased cardiac output, or cardiac index, lowered pulmonary artery pressures, decreased left ventricular end systolic and diastolic dimensions, decreased left and right ventricular wall stress, decreased wall tension, increased quality of life, and decreased disease-related morbidity or mortality.